

| | |
|---|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| | | | |
|---|--|---|---|
| 1. Name and Address of Reporting Person * <u>Hunter James Randolph Jr</u> (Last) (First) (Middle) <u>C/O TONIX PHARMACEUTICALS HOLDING CORP</u> <u>26 MAIN STREET, SUITE 101</u> (Street) <u>CHATHAM NJ 07928</u> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) <u>06/12/2025</u> | 3. Issuer Name and Ticker or Trading Symbol <u>Tonix Pharmaceuticals Holding Corp. [TNXP]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below) | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| | | | |
|---------------------------------|---|--|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-------------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| <u>Stock Option</u> | <u>06/06/2024</u> ⁽¹⁾ | <u>06/05/2033</u> | <u>Common Stock</u> | <u>2</u> | <u>6,240</u> | <u>D</u> | |
| <u>Stock Option</u> | <u>(2)</u> | <u>06/12/2035</u> | <u>Common Stock</u> | <u>7,740</u> | <u>34.54</u> | <u>D</u> | |

Explanation of Responses:

1. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and is fully vested.
2. The option vests on the date of the Company's 2026 annual meeting of stockholders, and was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.

/s/ Jessica Morris, attorney-in-fact 06/13/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.